2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/2iy5wruuedsh6.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/00yc7rcvua6a7.js","/_next/static/immutable/chunks/37ktb71aq3480.js","/_next/static/immutable/chunks/2d50b-7eu4558.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/2d6noqpp6ehas.js","/_next/static/immutable/chunks/1sx186c93bpzg.js","/_next/static/immutable/chunks/3dc-1n866s65i.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2w1bvggzb0ga8.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T998,To compare the effectiveness of romosozumab (ROMO) with parathyroid hormone (PTH) receptor agonists [teriparatide (TPTD)/abaloparatide (APTD)] in reducing fracture risk following osteoporosis treatment. A TriNetX cohort study assessed fracture and mortality risks using Kaplan-Meier analysis with hazard ratios (HRs) and 95% confidence intervals (CIs). After propensity score matching (n = 2,258 pairs), ROMO users had lower risks of osteoporotic fractures (HR: 0.711, 95% CI: 0.542-0.931) and hypercalcemia (HR = 0.707, 95% CI: 0.511-0.977) compared with PTH receptor agonists. Five subgroup analyses demonstrated a reduced fracture risk in the ROMO cohort among women (HR: 0.738), patients aged ≥ 65 years (HR: 0.652), individuals with a history of prior fractures (HR: 0.659), and those without chronic kidney disease (CKD) (HR: 0.731). Sensitivity analyses confirmed the robustness of the findings across different covariate adjustments, data sources, and extended follow-up, consistently showing a lower risk of hypercalcemia and nonsignificant trends toward reduced fracture risk in the ROMO cohort. Compared with PTH analogs, ROMO offers stronger short-term protection against osteoporotic fractures and hypercalcemia, particularly in older women with prior fractures. Nonetheless, cardiovascular safety, calcium metabolism, and sequential therapy require careful consideration for individualized treatment. Osteoporosis is a disease that makes bones weak and more likely to break, especially in older adults and women after menopause. This study compared two types of bone-strengthening medicines: romosozumab (ROMO) and parathyroid hormone (PTH) drugs, including teriparatide and abaloparatide. Researchers used a large health database to see which treatment better prevented bone fractures. They found that people taking ROMO had fewer fractures and fewer cases of high calcium levels in the blood than those taking PTH drugs. The benefits of ROMO were strongest in women, people aged 65 and older, and those who had fractures before. These results suggest that ROMO may offer stronger short-term protection against fractures compared with PTH drugs. However, doctors still need to consider possible side effects and each person’s overall health before choosing the best treatment. This study provides helpful information for patients and doctors in deciding how to manage osteoporosis and reduce the risk of fragility fractures.31:T817,Abstract Background To compare the effectiveness of romosozumab (ROMO) with parathyroid hormone (PTH) receptor agonists [teriparatide (TPTD)/abaloparatide (APTD)] in reducing fracture risk following osteoporosis treatment. Methods A TriNetX cohort study assessed fracture and mortality risks using Kaplan–Meier analysis with hazard ratios (HRs) and 95% confidence intervals (CIs). Results After propensity score matching (n = 2,258 pairs), ROMO users had lower risks of osteoporotic fractures (HR: 0.711, 95% CI: 0.542–0.931) and hypercalcemia (HR = 0.707, 95% CI: 0.511–0.977) compared with PTH receptor agonists. Five subgroup analyses demonstrated a reduced fracture risk in the ROMO cohort among women (HR: 0.738), patients aged ≥ 65 years (HR: 0.652), individuals with a history of prior fractures (HR: 0.659), and those without chronic kidney disease (CKD) (HR: 0.731). Sensitivity analyses confirmed the robustness of the findings across different covariate adjustments, data sources, and extended follow-up, consistently showing a lower risk of hypercalcemia and nonsignificant trends toward reduced fracture risk in the ROMO cohort. Conclusion Compared with PTH analogs, ROMO offers stronger short-term protection against osteoporotic fractures and hypercalcemia, particularly in older women with prior fractures. Nonetheless, cardiovascular safety, calcium metabolism, and sequential therapy require careful consideration for individualized treatment. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Forteo: brand Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Forteo (brand). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/brand/Forteo\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Brands\",\"item\":\"https://www.reachrx.ai/hub/tag/brand\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Forteo\",\"item\":\"https://www.reachrx.ai/hub/tag/brand/Forteo\"}]}}"}}]],["$","$L2f",null,{"title":"Forteo: Research & Clinical Takeaways","description":"See clinical studies on Forteo — efficacy, safety signals, dosing, and head-to-head results.","papers":[{"doi":"10.1002/ijgo.71203","pmid":"42464584","title":"Pregnancy‐ and lactation‐associated osteoporosis: A position statement of the\n IAPM\n ,\n IOF\n ,\n ECTS\n ,\n ESCEO\n ,\n IMS\n , and\n EMAS","journal_title":"International Journal of Gynecology & Obstetrics","journal_issn":"0020-7292","published_at":"2026-07-16T00:00:00.000Z","url":"https://doi.org/10.1002/ijgo.71203","source_score":5,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-21T13:34:27.700Z","updated_at":"2026-07-21T13:34:27.700Z","tags":[{"paper_doi":"10.1002/ijgo.71203","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"brand","value":"Evenity","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"brand","value":"Forteo","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"brand","value":"Prolia","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"brand","value":"Tymlos","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"category","value":"Obstetrics & Gynecology","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"condition","value":"Pregnancy- and Lactation-Associated Osteoporosis","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"condition","value":"Vertebral Fragility Fracture","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"generic","value":"abaloparatide","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"generic","value":"calcium","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"generic","value":"cholecalciferol","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"generic","value":"denosumab","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"generic","value":"romosozumab","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"generic","value":"teriparatide","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"modality","value":"Bisphosphonate","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"modality","value":"Bone Anabolic Agent","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"modality","value":"RANK Ligand Inhibitor","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"modality","value":"Sclerostin Inhibitor","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"study_design","value":"Clinical Practice Guideline / Position Statement","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"warning","value":"All pharmacological treatments discussed for PLO are off-label; clinical applicability depends heavily on individual patient context.","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"warning","value":"Study design classification as 'Clinical Practice Guideline / Position Statement' is applied; it is not a systematic review or meta-analysis, though it is based on a review of published evidence.","value_numeric":null},{"paper_doi":"10.1002/ijgo.71203","tag_type":"warning","value":"This is a consensus position statement, not a primary clinical trial; the level of evidence is expert opinion given the rarity of PLO and absence of RCTs.","value_numeric":null}],"summaries":{"what_studied":"This position statement from six major professional societies reviews the current evidence on pregnancy- and lactation-associated osteoporosis (PLO), covering diagnosis, assessment, and treatment of fragility fractures (most commonly vertebral) occurring in late pregnancy or early postpartum.","key_result":"Preferred first-line pharmacological agents are teriparatide/abaloparatide or romosozumab; second-choice options are denosumab followed by bisphosphonates or bisphosphonates alone — all used off-label. Calcium/vitamin D, considering stopping breastfeeding, and analgesia are first-step management. Bisphosphonates cross the placental barrier and persist in bone for years, so adverse effects on future pregnancies cannot be excluded.","limitations":"PLO is rare, so controlled comparative clinical trials are lacking; most evidence is from individual case series or small studies. All pharmacological treatments for PLO are off-label. Adverse effects of bisphosphonates on future pregnancies have not been reported but cannot be ruled out.","practice_takeaway":"For women with PLO, start with calcium/vitamin D supplementation, analgesia, and consider stopping breastfeeding; if bone-specific therapy is needed, prefer teriparatide, abaloparatide, or romosozumab over bisphosphonates, and ensure effective contraception during treatment. Always perform individualized risk assessment and rule out secondary causes of osteoporosis before initiating pharmacological therapy."}},{"doi":"10.1186/s13293-025-00817-1","pmid":"41484973","title":"Real-world evidence indicates romosozumab use is associated with a greater reduction in osteoporotic fractures than PTH (1–34) analogs in women","journal_title":"Biology of Sex Differences","journal_issn":"2042-6410","published_at":"2026-01-04T00:00:00.000Z","url":"https://doi.org/10.1186/s13293-025-00817-1","source_score":18,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-05","doi":"10.1186/s13293-025-00817-1","days":"7","issn":"2042-6410","rank":"9","field":"Clinical Medicine","score":"18","category":"Endocrinology & Metabolism","categories":["Endocrinology & Metabolism"],"_categories":["Endocrinology & Metabolism"]},"pubmed":{"doi":"10.1186/s13293-025-00817-1","title":"Real-world evidence indicates romosozumab use is associated with a greater reduction in osteoporotic fractures than PTH (1-34) analogs in women.","journal":"Biology of sex differences","methods":"","results":"After propensity score matching (n = 2,258 pairs), ROMO users had lower risks of osteoporotic fractures (HR: 0.711, 95% CI: 0.542-0.931) and hypercalcemia (HR = 0.707, 95% CI: 0.511-0.977) compared with PTH receptor agonists. Five subgroup analyses demonstrated a reduced fracture risk in the ROMO cohort among women (HR: 0.738), patients aged ≥ 65 years (HR: 0.652), individuals with a history of prior fractures (HR: 0.659), and those without chronic kidney disease (CKD) (HR: 0.731). Sensitivity analyses confirmed the robustness of the findings across different covariate adjustments, data sources, and extended follow-up, consistently showing a lower risk of hypercalcemia and nonsignificant trends toward reduced fracture risk in the ROMO cohort.","abstract":"$30","keywords":["Abaloparatide","Osteoporotic fracture","Romosozumab","Teriparatide","TriNetX"],"pubmed_id":"41484973","conclusions":"Compared with PTH analogs, ROMO offers stronger short-term protection against osteoporotic fractures and hypercalcemia, particularly in older women with prior fractures. Nonetheless, cardiovascular safety, calcium metabolism, and sequential therapy require careful consideration for individualized treatment.","publication_date":"2026-01-04T00:00:00"},"crossref":{"DOI":"10.1186/s13293-025-00817-1","URL":"https://doi.org/10.1186/s13293-025-00817-1","ISSN":["2042-6410"],"link":[{"URL":"https://link.springer.com/article/10.1186/s13293-025-00817-1","content-type":"text/html","content-version":"vor","intended-application":"text-mining"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Real-world evidence indicates romosozumab use is associated with a greater reduction in osteoporotic fractures than PTH (1–34) analogs in women"],"author":[{"given":"Ko-Hsiu","family":"Lu","sequence":"first","affiliation":[]},{"given":"Shiow-Ing","family":"Wang","sequence":"additional","affiliation":[]},{"given":"Shun-Fa","family":"Yang","sequence":"additional","affiliation":[]}],"funder":[{"id":[{"id":"10.13039/501100004699","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100004699","name":"Chung Shan Medical University Hospital","award":["CSH-2024-D-003"],"award-info":[{"award-number":["CSH-2024-D-003"]}],"doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2026,1,3]]},"member":"297","prefix":"10.1186","source":"Crossref","volume":null,"created":{"date-time":"2026-01-04T02:13:07Z","timestamp":1767492787000,"date-parts":[[2026,1,4]]},"indexed":{"date-time":"2026-01-04T02:14:36Z","timestamp":1767492876685,"date-parts":[[2026,1,4]]},"license":[{"URL":"https://creativecommons.org/licenses/by/4.0","start":{"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000,"date-parts":[[2026,1,3]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://creativecommons.org/licenses/by/4.0","start":{"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000,"date-parts":[[2026,1,3]]},"delay-in-days":0,"content-version":"am"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://link.springer.com/10.1186/s13293-025-00817-1"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"ArticleHistory","label":"Article History"},"label":"Received","order":1,"value":"29 October 2025"},{"name":"accepted","group":{"name":"ArticleHistory","label":"Article History"},"label":"Accepted","order":2,"value":"23 December 2025"},{"name":"first_online","group":{"name":"ArticleHistory","label":"Article History"},"label":"First Online","order":3,"value":"3 January 2026"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"},"order":1},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"},"order":2,"value":"This study was approved by the Institutional Review Board of Chung Shan Medical University Hospital (approval no. CS2-23208) and was reported in accordance with the RECORD (Reporting of Studies Conducted Using Observational Routinely Collected Health Data) guidelines."},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"},"order":3,"value":"Not Applicable."},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"},"order":4,"value":"The authors declare no competing interests."}],"deposited":{"date-time":"2026-01-04T02:13:13Z","timestamp":1767492793000,"date-parts":[[2026,1,4]]},"issn-type":[{"type":"electronic","value":"2042-6410"}],"published":{"date-parts":[[2026,1,3]]},"publisher":"Springer Science and Business Media LLC","reference":[{"DOI":"10.1016/S0140-6736(18)32112-3","key":"817_CR1","year":"2019","issue":null,"author":"JE Compston","volume":"393","first-page":"364","unstructured":"Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393:364–76.","article-title":null,"journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.7326/M22-1034","key":"817_CR2","year":"2023","issue":null,"author":"A Qaseem","volume":"176","first-page":"224","unstructured":"Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I, Shamliyan T, Cooney TG, Clinical Guidelines Committee of the American College of P, et al. Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians. Ann Intern Med. 2023;176:224–38.","article-title":null,"journal-title":"Ann Intern Med","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00774-024-01536-0","key":"817_CR3","year":"2025","issue":null,"author":"K Ebina","volume":"43","first-page":"3","unstructured":"Ebina K, Etani Y, Noguchi T, Nakata K, Okada S. Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis. J Bone Miner Metab. 2025;43:3–9.","article-title":null,"journal-title":"J Bone Miner Metab","doi-asserted-by":"crossref"},{"DOI":"10.1007/s11914-023-00793-8","key":"817_CR4","year":"2023","issue":null,"author":"PJ Kostenuik","volume":"21","first-page":"386","unstructured":"Kostenuik PJ, Binkley N, Anderson PA. Advances in osteoporosis therapy: focus on osteoanabolic agents, secondary fracture prevention, and perioperative bone health. Curr Osteoporos Rep. 2023;21:386–400.","article-title":null,"journal-title":"Curr Osteoporos Rep","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00198-018-4704-5","key":"817_CR5","year":"2019","issue":null,"author":"JA Kanis","volume":"30","first-page":"3","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, the Committees of Scientific A, National Societies of the International Osteoporosis F. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30:3–44.","article-title":null,"journal-title":"Osteoporos Int","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00774-020-01176-0","key":"817_CR6","year":"2021","issue":null,"author":"S Tanaka","volume":"39","first-page":"332","unstructured":"Tanaka S, Matsumoto T. Sclerostin: from bench to bedside. J Bone Miner Metab. 2021;39:332–40.","article-title":null,"journal-title":"J Bone Miner Metab","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(21)02646-5","key":"817_CR7","year":"2022","issue":null,"author":"IR Reid","volume":"399","first-page":"1080","unstructured":"Reid IR, Billington EO. Drug therapy for osteoporosis in older adults. Lancet. 2022;399:1080–92.","article-title":null,"journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1305224","key":"817_CR8","year":"2014","issue":null,"author":"MR McClung","volume":"370","first-page":"412","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370:412–20.","article-title":null,"journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(10)62349-5","key":"817_CR9","year":"2011","issue":null,"author":"TD Rachner","volume":"377","first-page":"1276","unstructured":"Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377:1276–87.","article-title":null,"journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.3949/ccjm.88a.21011","key":"817_CR10","year":"2021","issue":null,"author":"PD Miller","volume":"88","first-page":"489","unstructured":"Miller PD, Lewiecki EM, Krohn K, Schwartz E. Teriparatide: label changes and identifying patients for long-term use. Cleve Clin J Med. 2021;88:489–93.","article-title":null,"journal-title":"Cleve Clin J Med","doi-asserted-by":"crossref"},{"DOI":"10.1002/jbm4.10665","key":"817_CR11","year":"2022","issue":null,"author":"JH Krege","volume":"6","first-page":null,"unstructured":"Krege JH, Gilsenan AW, Komacko JL, Kellier-Steele N. Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates. JBMR Plus. 2022;6:e10665.","article-title":null,"journal-title":"JBMR Plus","doi-asserted-by":"crossref"},{"DOI":null,"key":"817_CR12","year":"2025","issue":null,"author":"H Vall","volume":null,"first-page":null,"unstructured":"Vall H, Patel P, Parmar M. Teriparatide. Treasure Island (FL): StatPearls; 2025.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/S0140-6736(17)32137-2","key":"817_CR13","year":"2018","issue":null,"author":"DL Kendler","volume":"391","first-page":"230","unstructured":"Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391:230–40.","article-title":null,"journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00198-020-05463-4","key":"817_CR14","year":"2020","issue":null,"author":"JJ Body","volume":"31","first-page":"1935","unstructured":"Body JJ, Marin F, Kendler DL, Zerbini CAF, Lopez-Romero P, Moricke R, et al. Efficacy of teriparatide compared with risedronate on FRAX((R))-defined major osteoporotic fractures: results of the VERO clinical trial. Osteoporos Int. 2020;31:1935–42.","article-title":null,"journal-title":"Osteoporos Int","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJM200105103441904","key":"817_CR15","year":"2001","issue":null,"author":"RM Neer","volume":"344","first-page":"1434","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–41.","article-title":null,"journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2016.11136","key":"817_CR16","year":"2016","issue":null,"author":"PD Miller","volume":"316","first-page":"722","unstructured":"Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316:722–33.","article-title":null,"journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1007/s40265-019-01072-6","key":"817_CR17","year":"2019","issue":null,"author":"A Markham","volume":"79","first-page":"471","unstructured":"Markham A. Romosozumab: first global approval. Drugs. 2019;79:471–6.","article-title":null,"journal-title":"Drugs","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1708322","key":"817_CR18","year":"2017","issue":null,"author":"KG Saag","volume":"377","first-page":"1417","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377:1417–27.","article-title":null,"journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1607948","key":"817_CR19","year":"2016","issue":null,"author":"F Cosman","volume":"375","first-page":"1532","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375:1532–43.","article-title":null,"journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1359/jbmr.080506","key":"817_CR20","year":"2008","issue":null,"author":"BM Obermayer-Pietsch","volume":"23","first-page":"1591","unstructured":"Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 2008;23:1591–600.","article-title":null,"journal-title":"J Bone Miner Res","doi-asserted-by":"crossref"},{"DOI":"10.1210/clinem/dgae484","key":"817_CR21","year":"2025","issue":null,"author":"MC Hartz","volume":"110","first-page":"e1640","unstructured":"Hartz MC, Johannessen FB, Harslof T, Langdahl BL. The effectiveness and safety of romosozumab and teriparatide in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2025;110:e1640-52.","article-title":null,"journal-title":"J Clin Endocrinol Metab","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00198-022-06545-1","key":"817_CR22","year":"2022","issue":null,"author":"K Ebina","volume":"33","first-page":"2441","unstructured":"Ebina K, Etani Y, Tsuboi H, Nagayama Y, Kashii M, Miyama A, et al. Impact of the duration of previous osteoporosis treatment on the effect of romosozumab in patients with postmenopausal osteoporosis. Osteoporos Int. 2022;33:2441–3.","article-title":null,"journal-title":"Osteoporos Int","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.bone.2020.115574","key":"817_CR23","year":"2020","issue":null,"author":"K Ebina","volume":"140","first-page":null,"unstructured":"Ebina K, Hirao M, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S, et al. Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone. 2020;140:115574.","article-title":null,"journal-title":"Bone","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jbspin.2021.105219","key":"817_CR24","year":"2021","issue":null,"author":"K Ebina","volume":"88","first-page":null,"unstructured":"Ebina K, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S, Miyama A, et al. Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis. Joint Bone Spine. 2021;88:105219.","article-title":null,"journal-title":"Joint Bone Spine","doi-asserted-by":"crossref"},{"DOI":"10.1002/jbmr.3176","key":"817_CR25","year":"2017","issue":null,"author":"TM Keaveny","volume":"32","first-page":"1956","unstructured":"Keaveny TM, Crittenden DB, Bolognese MA, Genant HK, Engelke K, Oliveri B, et al. Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass. J Bone Miner Res. 2017;32:1956–62.","article-title":null,"journal-title":"J Bone Miner Res","doi-asserted-by":"crossref"},{"DOI":"10.1002/jbmr.2932","key":"817_CR26","year":"2017","issue":null,"author":"HK Genant","volume":"32","first-page":"181","unstructured":"Genant HK, Engelke K, Bolognese MA, Mautalen C, Brown JP, Recknor C, et al. Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res. 2017;32:181–7.","article-title":null,"journal-title":"J Bone Miner Res","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(17)31613-6","key":"817_CR27","year":"2017","issue":null,"author":"BL Langdahl","volume":"390","first-page":"1585","unstructured":"Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390:1585–94.","article-title":null,"journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2213-8587(20)30159-5","key":"817_CR28","year":"2020","issue":null,"author":"DM Black","volume":"8","first-page":"672","unstructured":"Black DM, Bauer DC, Vittinghoff E, Lui LY, Grauer A, Marin F, et al. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. Lancet Diabetes Endocrinol. 2020;8:672–82.","article-title":null,"journal-title":"Lancet Diabetes Endocrinol","doi-asserted-by":"crossref"},{"DOI":"10.1080/00273171.2011.568786","key":"817_CR29","year":"2011","issue":null,"author":"PC Austin","volume":"46","first-page":"399","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46:399–424.","article-title":null,"journal-title":"Multivar Behav Res","doi-asserted-by":"crossref"},{"DOI":"10.1093/ejendo/lvaf013","key":"817_CR30","year":"2025","issue":null,"author":"KH Lu","volume":"192","first-page":"180","unstructured":"Lu KH, Wang SI, Yang SF. Denosumab withdrawal increases vertebral fracture and mortality risk compared with zoledronate. Eur J Endocrinol. 2025;192:180–90.","article-title":null,"journal-title":"Eur J Endocrinol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2015.13480","key":"817_CR31","year":"2015","issue":null,"author":"JS Haukoos","volume":"314","first-page":"1637","unstructured":"Haukoos JS, Lewis RJ. The propensity score. JAMA. 2015;314:1637–8.","article-title":null,"journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":null,"key":"817_CR32","year":"2025","issue":null,"author":"KH Lu","volume":"77","first-page":null,"unstructured":"Lu KH, Hsieh YH, Lin RC, Tsai MY, Yang SF. Melatonin: a potential therapy for osteoporosis with insights into molecular mechanisms. J Pineal Res. 2025;77:e70062.","article-title":null,"journal-title":"J Pineal Res","doi-asserted-by":null},{"DOI":"10.1038/nrendo.2016.71","key":"817_CR33","year":"2016","issue":null,"author":"LI Plotkin","volume":"12","first-page":"593","unstructured":"Plotkin LI, Bellido T. Osteocytic signalling pathways as therapeutic targets for bone fragility. Nat Rev Endocrinol. 2016;12:593–605.","article-title":null,"journal-title":"Nat Rev Endocrinol","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1916525","key":"817_CR34","year":"2020","issue":null,"author":"DM Black","volume":"383","first-page":"743","unstructured":"Black DM, Geiger EJ, Eastell R, Vittinghoff E, Li BH, Ryan DS, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med. 2020;383:743–53.","article-title":null,"journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1210/clinem/dgae173","key":"817_CR35","year":"2025","issue":null,"author":"J Stokar","volume":"110","first-page":"e861","unstructured":"Stokar J, Szalat A. Cardiovascular safety of romosozumab vs PTH analogues for osteoporosis treatment: a propensity-score-matched cohort study. J Clin Endocrinol Metab. 2025;110:e861-7.","article-title":null,"journal-title":"J Clin Endocrinol Metab","doi-asserted-by":"crossref"},{"DOI":"10.1210/jc.2019-00192","key":"817_CR36","year":"2019","issue":null,"author":"P Barrionuevo","volume":"104","first-page":"1623","unstructured":"Barrionuevo P, Kapoor E, Asi N, Alahdab F, Mohammed K, Benkhadra K, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab. 2019;104:1623–30.","article-title":null,"journal-title":"J Clin Endocrinol Metab","doi-asserted-by":"crossref"},{"DOI":"10.1210/jc.2017-02163","key":"817_CR37","year":"2018","issue":null,"author":"EM Lewiecki","volume":"103","first-page":"3183","unstructured":"Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, et al. A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab. 2018;103:3183–93.","article-title":null,"journal-title":"J Clin Endocrinol Metab","doi-asserted-by":"crossref"},{"DOI":"10.1080/14740338.2023.2173737","key":"817_CR38","year":"2023","issue":null,"author":"M Di Monaco","volume":"22","first-page":"103","unstructured":"Di Monaco M, Castiglioni C, Bardesono F. Letter to the editor: consideration on: “What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?” by Reid I.R. Expert Opin Drug Saf. 2023;22:103–4.","article-title":null,"journal-title":"Expert Opin Drug Saf","doi-asserted-by":"crossref"},{"DOI":"10.1080/14740338.2022.2160445","key":"817_CR39","year":"2022","issue":null,"author":"IR Reid","volume":"21","first-page":"1441","unstructured":"Reid IR. What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab? Expert Opin Drug Saf. 2022;21:1441–3.","article-title":null,"journal-title":"Expert Opin Drug Saf","doi-asserted-by":"crossref"},{"DOI":"10.1093/jbmr/zjaf010","key":"817_CR40","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Tominaga R, Ikenoue T, Ishii R, Niihata K, Aita T, Okuda T, Shimizu S, Taguri M, Kurita N. Comparative cardiovascular safety of romosozumab versus bisphosphonates in Japanese patients with osteoporosis: a new-user, active comparator design with instrumental variable analyses. J Bone Miner Res. 2025.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.3390/jcm10081660","key":"817_CR41","year":"2021","issue":null,"author":"A Vestergaard Kvist","volume":null,"first-page":null,"unstructured":"Vestergaard Kvist A, Faruque J, Vallejo-Yague E, Weiler S, Winter EM, Burden AM. Cardiovascular safety profile of romosozumab: a pharmacovigilance analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS). J Clin Med. 2021. https://doi.org/10.3390/jcm10081660.","article-title":null,"journal-title":"J Clin Med","doi-asserted-by":"publisher"},{"DOI":"10.1177/87551225221144960","key":"817_CR42","year":"2023","issue":null,"author":"K Kotake","volume":"39","first-page":"23","unstructured":"Kotake K, Mitsuboshi S, Omori Y, Kawakami Y, Kawakami Y. Evaluation of risk of cardiac or cerebrovascular events in romosozumab users focusing on comorbidities: analysis of the Japanese Adverse Drug Event Report Database. J Pharm Technol. 2023;39:23–8.","article-title":null,"journal-title":"J Pharm Technol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.bone.2022.116610","key":"817_CR43","year":"2023","issue":null,"author":"AH Seeto","volume":"167","first-page":null,"unstructured":"Seeto AH, Tadrous M, Gebre AK, Lewis JR, Fink HA, Ebeling PR, et al. Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: a systematic review and Bayesian network meta-analysis. Bone. 2023;167:116610.","article-title":null,"journal-title":"Bone","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(15)61120-5","key":"817_CR44","year":"2015","issue":null,"author":"BZ Leder","volume":"386","first-page":"1147","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015;386:1147–55.","article-title":null,"journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1002/jbmr.3198","key":"817_CR45","year":"2017","issue":null,"author":"JN Tsai","volume":"32","first-page":"2001","unstructured":"Tsai JN, Nishiyama KK, Lin D, Yuan A, Lee H, Bouxsein ML, et al. Effects of denosumab and teriparatide transitions on bone microarchitecture and estimated strength: the DATA-Switch HR-pQCT study. J Bone Miner Res. 2017;32:2001–9.","article-title":null,"journal-title":"J Bone Miner Res","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.bone.2017.03.006","key":"817_CR46","year":"2017","issue":null,"author":"BZ Leder","volume":"98","first-page":"54","unstructured":"Leder BZ, Tsai JN, Jiang LA, Lee H. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the Denosumab and Teriparatide Follow-up study (DATA-Follow-up). Bone. 2017;98:54–8.","article-title":null,"journal-title":"Bone","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jocd.2017.05.007","key":"817_CR47","year":"2017","issue":null,"author":"JN Tsai","volume":"20","first-page":"507","unstructured":"Tsai JN, Jiang LA, Lee H, Hans D, Leder BZ. Effects of teriparatide, denosumab, or both on spine trabecular microarchitecture in DATA-Switch: a randomized controlled trial. J Clin Densitom. 2017;20:507–12.","article-title":null,"journal-title":"J Clin Densitom","doi-asserted-by":"crossref"},{"DOI":"10.1359/JBMR.050501","key":"817_CR48","year":"2005","issue":null,"author":"R Prince","volume":"20","first-page":"1507","unstructured":"Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res. 2005;20:1507–13.","article-title":null,"journal-title":"J Bone Miner Res","doi-asserted-by":"crossref"}],"short-title":[],"update-policy":"https://doi.org/10.1007/springer_crossmark_policy","alternative-id":["817"],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"original-title":[],"container-title":["Biology of Sex Differences"],"reference-count":48,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,3]]},"references-count":48,"short-container-title":["Biol Sex Differ"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1186/s13293-025-00817-1","is_oa":true,"title":"Real-world evidence indicates romosozumab use is associated with a greater reduction in osteoporotic fractures than PTH (1–34) analogs in women","updated":"2026-01-05T00:44:41+00:00","published_date":"2026-01-03","best_oa_location":{"url":"https://doi.org/10.1186/s13293-025-00817-1","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1186/s13293-025-00817-1"}}},"created_at":"2026-01-11T11:19:33.869Z","updated_at":"2026-01-11T11:19:33.869Z","tags":[{"paper_doi":"10.1186/s13293-025-00817-1","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1186/s13293-025-00817-1","tag_type":"brand","value":"Evenity","value_numeric":null},{"paper_doi":"10.1186/s13293-025-00817-1","tag_type":"brand","value":"Forteo","value_numeric":null},{"paper_doi":"10.1186/s13293-025-00817-1","tag_type":"brand","value":"Tymlos","value_numeric":null},{"paper_doi":"10.1186/s13293-025-00817-1","tag_type":"category","value":"Endocrinology & Metabolism","value_numeric":null},{"paper_doi":"10.1186/s13293-025-00817-1","tag_type":"condition","value":"Osteoporosis","value_numeric":null},{"paper_doi":"10.1186/s13293-025-00817-1","tag_type":"generic","value":"abaloparatide","value_numeric":null},{"paper_doi":"10.1186/s13293-025-00817-1","tag_type":"generic","value":"romosozumab","value_numeric":null},{"paper_doi":"10.1186/s13293-025-00817-1","tag_type":"generic","value":"teriparatide","value_numeric":null},{"paper_doi":"10.1186/s13293-025-00817-1","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1186/s13293-025-00817-1","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1186/s13293-025-00817-1","tag_type":"modality","value":"PTH Receptor Agonist","value_numeric":null},{"paper_doi":"10.1186/s13293-025-00817-1","tag_type":"modality","value":"Sclerostin Inhibitor","value_numeric":null},{"paper_doi":"10.1186/s13293-025-00817-1","tag_type":"sample_size","value":"n=4,516","value_numeric":4516},{"paper_doi":"10.1186/s13293-025-00817-1","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1186/s13293-025-00817-1","tag_type":"study_design","value":"Retrospective Cohort","value_numeric":null},{"paper_doi":"10.1186/s13293-025-00817-1","tag_type":"warning","value":"Counts <10 were masked in several analyses, and several hip fracture/mortality results were unavailable.","value_numeric":null},{"paper_doi":"10.1186/s13293-025-00817-1","tag_type":"warning","value":"Male subgroup was very small (22 matched pairs), limiting sex-specific estimates.","value_numeric":null},{"paper_doi":"10.1186/s13293-025-00817-1","tag_type":"warning","value":"Real-world database cohort with propensity score matching; not randomized.","value_numeric":null}],"summaries":{"what_studied":"A real-world TriNetX cohort compared romosozumab with PTH receptor agonists (teriparatide/abaloparatide) for osteoporotic fracture and hypercalcemia risk over 1 year, using propensity score–matched pairs (n=2,258 per group), with subgroup and sensitivity analyses and an extended follow-up to 730 days.","key_result":"After matching (n=2,258 pairs), romosozumab was associated with lower osteoporotic fracture risk (HR 0.711, 95% CI 0.542–0.931) and lower hypercalcemia risk (HR 0.707, 95% CI 0.511–0.977) versus PTH agonists; reductions were observed in women (HR 0.738) and those ≥65 years (HR 0.652).","limitations":"The male subgroup was very small (n=22 matched pairs), with many outcomes unavailable; several analyses had masked counts (<10) and the extended follow-up showed nonsignificant fracture differences despite lower hypercalcemia risk.","practice_takeaway":"Romosozumab provided stronger short-term protection against osteoporotic fractures and hypercalcemia than teriparatide/abaloparatide, particularly in older women and those with prior fractures; selection should also consider cardiovascular safety, calcium metabolism, and plans for sequential therapy."}}],"initialOffset":2,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"brand","value":"Forteo"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Brands","href":"/hub/tag/brand"},{"name":"Forteo"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"brand","hub_tag_value":"Forteo"}}}]]

Papers